Concepedia

Author

Fernando Rivera

Marqués de Valdecilla University Hospital

Also Known As

Almudena Garcia, F. Rivera, FERNANDO JANDETE RIVERA, Fernando Rivera, P. Cerdá, Paula Cerdà

49

Publications

3.3K

Citations

17

H-Index

33

Concepts

All Affiliations

Marqués de Valdecilla University HospitalVall d'Hebron Hospital UniversitariHospital Universitario Central de AsturiasThe Maria Sklodowska-Curie National Research Institute of OncologyHospital Universitario 12 De Octubre
FR

About

Fernando Rivera is an author at Marqués de Valdecilla University Hospital specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

12

2.2K

2

Gastroenterology

6

6

1.4K

3

Health Sciences

4

4

566

4

Public Health

1

1

10

5

Immunology

1

1

12

Fernando Rivera

×

17

Publications

2.7K

Citations

15

H-Index

YearCitations

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang,

The Lancet

2018

1.3K

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez,

The Lancet Oncology

2023

521

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

Lisa Licitra, Fernando Rivera, Éva Remenár,

Annals of Oncology

2010

229

Level of <i>HER2</i> Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab

Carlos Gómez-Martín, Carlos Plaza, Roberto Pazo-Cid,

Journal of Clinical Oncology

2013

195

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer

Yelena Y. Janjigian, Salah-Eddin Al-Batran, Zev A. Wainberg,

New England Journal of Medicine

2025

130

Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

Fernando Rivera, C. Romero, Paula Jiménez‐Fonseca,

Cancer Chemotherapy and Pharmacology

2019

63

Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab

Asunción Díaz-Serrano, Bárbara Angulo, Carolina Domínguez,

The Oncologist

2018

51

SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019)

Marta Martín-Richard, Alberto Carmona‐Bayonas, Ana Custodio,

Clinical & Translational Oncology

2020

34

SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016)

Marta Martín-Richard, Robert Díaz Beveridge, Virginia Arrazubi,

Clinical & Translational Oncology

2016

28

NEOHX study: Perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER-2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma—18 m DFS analysis.

Fernando Rivera, Paula Jiménez‐Fonseca, Pilar Alfonso,

Journal of Clinical Oncology

2015

25

Page 1